Braveheart Bio prices IPO at $18 per share, raises $382.5M
Braveheart Bio (BRVE) priced its IPO at $18.00 per share for 21.25 million shares, raising about $382.5 million in gross proceeds, per the company. Underwriters received a 30-day option for up to 3.1875 million additional shares. Shares were set to start trading on Nasdaq on Aug. 6, 2026, with closing Aug. 7.
How this was made
The 30-second read
Why it matters
The IPO terms (price, share count, gross proceeds, and underwriter option) and the expected Nasdaq start date are the actionable items for near-term positioning in BRVE around listing day.
Market read
This is a primary capital-markets disclosure for BRVE, setting the stage for listing-day liquidity and volatility.
What to watch
Traders will want the final prospectus details (use of proceeds, cash runway, trial milestones, and risk factors) and any indications of underwriter allocation strength, none of which are provided here.
Background
Braveheart Bio is a clinical-stage biopharmaceutical company developing BHB-1893, an oral small-molecule cardiac myosin inhibitor for hypertrophic cardiomyopathy.
Ticker impact
Braveheart Bio priced its IPO at $18 per share, raising $382.5M, with Nasdaq trading expected to start Aug 6, 2026.
Likely elevated opening volatility around the Aug 6 listing, with direction driven by IPO demand versus peers and broader risk appetite.
The article discloses concrete IPO terms (price, shares, gross proceeds, underwriter option, and start/close dates). That is sufficient for near-term trading planning, but it lacks demand/valuation details that would sharpen direction.
Market effects
Adds a new cardiovascular biopharma listing, which can marginally affect sentiment around early-stage cardiac therapeutics and IPO appetite in biotech.
Primarily US-focused via Nasdaq listing; limited spillover beyond biotech IPO flows.
Low global relevance; mostly a US capital-markets event.
Counterpoint
IPO pricing alone does not guarantee post-listing performance; if demand was weak or valuation is rich, shares can fade quickly after the lockup/initial hype period.
Key entities
- companyBraveheart Bio, Inc.
Clinical-stage biopharmaceutical company pricing an IPO and preparing for Nasdaq trading.
- product_candidateBHB-1893
Oral small-molecule cardiac myosin inhibitor in development for hypertrophic cardiomyopathy.
- financial_advisorGoldman Sachs & Co. LLC
Joint book-running manager for the IPO.
